Hoe verhoudt BLE's PS Ratio zich tot zijn concurrenten?

BLE is een goede waarde op basis van zijn Price-To-Sales Ratio (1.4x) vergeleken met het gemiddelde van gelijken (7.8x).

Hoe verhoudt BLE's PS Ratio zich tot andere bedrijven in de DE Biotechs industrie?

BLE is een goede waarde op basis van de Price-To-Sales -ratio ( 1.4 x) vergeleken met het German Biotechs -industriegemiddelde ( 12.6 x).

Wat is BLE's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

BLE is een goede waarde op basis van de Price-To-Sales -ratio ( 1.4 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 3.2 x).

Wat is de reële prijs van BLE als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

BLE ( €0.33 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( €8.35 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling ligt meer dan 20 % hoger dan de huidige aandelenkoers, maar analisten zijn het statistisch gezien niet eens over de overeengekomen marge.

bluebird bio (MUN:BLE) - Aandelenkoers, Nieuws & Analyse

BLE Overzicht aandelen

bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en verkoopt gentherapieën voor genezende ernstige genetische ziekten in de Verenigde Staten. Meer informatie

BLE fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Verhandeld tegen 96% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 41.53% per jaar groeien

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

bluebird bio, Inc. Concurrenten

2invest

XTRA:2INV

€62.7m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Medigene

XTRA:MDG1

€17.4m

co.don

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor bluebird bio
Historische aandelenkoersen
Huidige aandelenkoers	US$0.33
52 Week Hoogtepunt	US$4.75
52 Week Laag	US$0.29
Bèta	0.80
11 maand verandering	-28.58%
3 maanden verandering	-41.05%
1 Jaar Verandering	n/a
33 jaar verandering	-96.37%
5 jaar verandering	n/a
Verandering sinds IPO	-97.98%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BLE	DE Biotechs	DE Markt
7D	15.0%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BLE presteerde ten opzichte van de German Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BLE presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is BLE's price volatile compared to industry and market?
BLE volatility
BLE Average Weekly Movement	13.1%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van BLE is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van BLE is het afgelopen jaar gedaald van 21% naar 13%, maar is nog steeds hoger dan 75% van de German -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc., een biotechnologiebedrijf, onderzoekt, ontwikkelt en commercialiseert gentherapieën voor curatieve ernstige genetische ziekten in de Verenigde Staten. De productkandidaten van het bedrijf voor ernstige genetische ziekten omvatten ZYNTEGLO (betibeglogene autotemcel) voor de behandeling van transfusie-afhankelijke ß-thalassemie; lovotibeglogene autotemcel voor de behandeling van sikkelcelziekte (SCD); en SKYSONA (elivaldogene autotemcel) voor de behandeling van cerebrale adrenoleukodystrofie. Haar klinische ontwikkelingsprogramma's omvatten HGB-205, HGB-206 en HGB-210 om de veiligheid en doeltreffendheid van lovo-cel te evalueren bij de behandeling van patiënten met SCD; en HGB-204, HGB-205, HGB-207 en HGB-212 om de veiligheid en doeltreffendheid van beti-cel te evalueren bij de behandeling van patiënten met ß-thalassemie.

bluebird bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van bluebird bio zich tot de beurswaarde?
BLE fundamentele statistieken
Marktkapitalisatie	€68.67m
Inkomsten(TTM)	-€279.50m
Inkomsten(TTM)	€50.70m

1.4x

P/S-verhouding

-0.2x

Koers/Winstverhouding

Is BLE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BLE resultatenrekening (TTM)
Inkomsten	US$53.12m
Kosten van inkomsten	US$78.78m
Brutowinst	-US$25.66m
Overige uitgaven	US$267.16m
Inkomsten	-US$292.82m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.51
Brutomarge	-48.31%
Nettowinstmarge	-551.25%
Schuld/Eigen Vermogen Verhouding	-1,394.4%

Hoe presteerde BLE op de lange termijn?

Bekijk historische prestaties en vergelijking

BLE Overzicht aandelen

Beloningen

Risicoanalyse

bluebird bio, Inc. Concurrenten

XTRA:2INV

€62.7m

XTRA:HPHA

€105.8m

XTRA:MDG1

€17.4m

XTRA:CNW

€6.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer